Anti-inflammatory properties of desloratadine

被引:33
作者
Agrawal, DK [1 ]
机构
[1] Creighton Univ, Sch Med, Ctr Allergy Asthma & Immunol, Omaha, NE 68178 USA
关键词
allergic diseases; anti-inflammatory properties; desloratadine; pathophysiology;
D O I
10.1111/j.1365-2222.2004.02026.x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background Allergic rhinitis (AR) is associated with robust infiltration of immune cells and mediators that may contribute to clinical manifestations of the disease. Objective To review the complex immune effector mechanisms involved in the allergic response and discuss their effects on the pathophysiological and clinical manifestations of AR. Desloratadine, a novel antihistamine, was used as a probe with the goal of attaining a better understanding of the inflammatory processes underlying the allergic response. Methods Data were obtained from abstracts and peer-reviewed journals. The pathophysiology of the allergic response has been extensively studied. This paper presents only data from studies that used desloratadine at physiologically relevant concentrations. Results Key mediators involved in the allergic response and in pathophysiological and clinical manifestations of the immune response were reviewed. Desloratadine was used as a probe to further elucidate the mechanisms involved during an allergic response. Conclusions Some have proposed a link between the pathophysiology of AR and the clinical manifestation of symptoms. Desloratadine, a new-generation antihistamine, has demonstrated anti-inflammatory effects in vitro; indeed, desloratadine is capable of intervening at various points in the immune cascade. Although in vitro results do not necessarily correlate with clinical efficacy, the anti-inflammatory properties of desloratadine may contribute to its efficacy in patients with AR, allergy-induced asthma, and other related allergic conditions. Antihistamines that modulate in the immune system at various stages may optimize treatment of allergic disease.
引用
收藏
页码:1342 / 1348
页数:7
相关论文
共 39 条
[31]   Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study [J].
Ring, J ;
Hein, R ;
Gauger, A ;
Bronsky, E ;
Miller, B .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2001, 40 (01) :72-76
[32]   Antihistamines in late-phase clinical development for allergic disease [J].
Salmun, LM .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (02) :259-273
[33]   Desloratadine in the treatment of nasal congestion in seasonal allergic rhinitis - Preclinical and clinical evidence [J].
Scadding, GK .
CLINICAL DRUG INVESTIGATION, 2002, 22 (Suppl 2) :21-32
[34]   Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine [J].
Schroeder, JT ;
Schleimer, RP ;
Lichtenstein, LM ;
Kreutner, W .
CLINICAL AND EXPERIMENTAL ALLERGY, 2001, 31 (09) :1369-1377
[35]   Inhibitory effect of cetirizine on cytokine-enhanced in vitro eosinophil survival [J].
Sedgwick, JB ;
Busse, WW .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1997, 78 (06) :581-585
[36]   Consensus statement on the treatment of allergic rhinitis [J].
van Cauwenberge, P ;
Bachert, C ;
Passalacqua, G ;
Bousquet, J ;
Canonica, GW ;
Durham, SR ;
Fokkens, WJ ;
Howarth, PH .
ALLERGY, 2000, 55 (02) :116-134
[37]   INHIBITORY ACTIVITY OF LORATADINE AND DESCARBOETHOXYLORATADINE ON EXPRESSION OF ICAM-1 AND HLA-DR BY NASAL EPITHELIAL-CELLS [J].
VIGNOLA, AM ;
CRAMPETTE, L ;
MONDAIN, M ;
SAUVERE, G ;
CZARLEWSKI, W ;
BOUSQUET, J ;
CAMPBELL, AM .
ALLERGY, 1995, 50 (03) :200-203
[38]  
WU R, 2003, J ALLERGY CLIN IMMUN, V111, P283
[39]  
2000, PATIENT CARE FAL, P8